Information Provided By:
Fly News Breaks for March 4, 2020
Mar 4, 2020 | 10:44 EDT
Roth Capital analyst Yasmeen Rahimi raised the firm's price target on Arcturus Therapeutics to $24 from $14 and keeps a Buy rating on the shares. With global public health concerns around continued COVID-19 infection, the company announced a partnership with Duke-NUS to utilize its STARR technology for vaccine development, the analyst notes. With STARR incorporating the essential elements of LUNAR mRNA design, Rahimi sees a potential dataset in COVID-19 as an expedited shot on goal for validation of its mRNA platform.
News For ARCT From the Last 2 Days
There are no results for your query ARCT